922MO Updated ongoing phase I/II clinical trial results of AMT-116, a first-in-class anti-CD44v9 antibody-drug conjugate (ADC), in patients with advanced solid tumors.
Saved in:
| Title: | 922MO Updated ongoing phase I/II clinical trial results of AMT-116, a first-in-class anti-CD44v9 antibody-drug conjugate (ADC), in patients with advanced solid tumors. |
|---|---|
| Authors: | Song, Z.1 (AUTHOR), Park, J.2 (AUTHOR), Zhang, Y.3 (AUTHOR), Coward, J.4 (AUTHOR), Voskoboynik, M.5 (AUTHOR), Kichenadasse, G.6 (AUTHOR), Parakh, S.7 (AUTHOR), Powderly, J.8 (AUTHOR), Lin, R.9 (AUTHOR), Lin, X.10 (AUTHOR), Wei, T.11 (AUTHOR), Qu, S.12 (AUTHOR), Richardson, G.13 (AUTHOR), Guo, Y.14 (AUTHOR), Orr, D.15 (AUTHOR), Yu, X.1 (AUTHOR), Shen, L.16 (AUTHOR), Liu, S.17 (AUTHOR), Huang, Y.18 (AUTHOR), Liu, S-H.17 (AUTHOR) |
| Source: | Annals of Oncology. 2025 Supplement 2, Vol. 36, pS603-S603. 1p. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
